(Source: FibroGen Inc) TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) ('Astellas') and FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), today announced the dosing of the first patient in Phase 3 trials in Japan of roxadustat (development code: ASP1517/FG-4592) for treatment of anemia in chronic kidney disease (CKD), which triggered a $10 million milestone payment from Astellas to FibroGen. The initiation of Phase 3 studies in Japan follows the positive results from two Phase 2 studies in Japan of roxadustat in CKD patients on dialysis and in CKD patients not on dialysis. In the Phase 2 studies in Japan of CKD patients receiving dialysis and not receiving...
↧